TORONTO, March 29, 2022 /PRNewswire/ – Diamond Therapeutics Inc., a drug development company focused on non-psychedelic doses of psilocybin for use in the treatment of mental health, announces the completion of last patient last visit (LPLV) in its Phase 1 clinical trial of low doses of psilocybin. LPLV is the date upon which the last subject completes a clinical study. The study’s final patient…


Previous articleDelix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank
Next articleMindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin